A study with cell therapy treatment (Megadose Drug Combination) to significantly reduce the need for immune suppression treatment for both donor-matched and mismatched bone marrow transplant patients

Trial Profile

A study with cell therapy treatment (Megadose Drug Combination) to significantly reduce the need for immune suppression treatment for both donor-matched and mismatched bone marrow transplant patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Stem cell therapies (Primary)
  • Indications Bone marrow transplant rejection; Engraftment
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Dec 2015 New trial record
    • 11 Nov 2015 According to a Cell Source media release, the first patient has been treated in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top